ea0099ep270 | Pituitary and Neuroendocrinology | ECE2024
Bogazzi Fausto
, Cannavo Salvatore
, Giordano Carla
, Detomas Mario
, Scaroni Carla
, Raverot Gerald
, Schopohl Jochen
, Georgescu Carmen
, Piacentini Andrea
, Mueller Arnd
, Stermenska Julia
, Bertherat Jerome
Introduction: Subcutaneous (sc) pasireotide effectively reduces cortisol levels and is generally well tolerated in Cushings disease (CD) patients, as demonstrated by a Phase III study (NCT00434148). We report data from a non-interventional, multinational study (NCT02310269) evaluating long-term safety and efficacy of pasireotide sc for CD patients.Methods: Adults with CD, for whom surgery has failed or is not an option, were analysed by time of pas...